Understand the source comparison
Peptides for Chronic Fatigue Syndrome: Research Comparison
Thymalin T-regulatory cell modulation, thymulin restoration, IL-6 reduction Observational studies, small RCTs (n=40–80) 20 days (10 injections) Requires zinc cofactor saturation; IM administration only Strongest evidence for immune-mediated CFS subtypes with e
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- Thymalin
- T-regulatory cell modulation, thymulin restoration, IL-6 reduction
- Observational studies, small RCTs (n=40–80)
- 20 days (10 injections)
- Requires zinc cofactor saturation; IM administration only
- Strongest evidence for immune-mediated CFS subtypes with elevated inflammatory markers
- Cerebrolysin
- Mitochondrial biogenesis via PGC-1α, BDNF-like neuroprotection, oxidative stress reduction
- Preclinical + limited clinical (neurodegenerative models)
- 4–8 weeks (10–20 IV sessions)
- IV administration; effect plateau around session 12
- Best option for CFS with pronounced post-exertional malaise and mitochondrial dysfunction markers
- Dihexa
- Synaptic density restoration, HGF receptor binding, dendritic spine growth
- Preclinical models; no CFS-specific human trials
- 4–6 weeks (daily oral)
- No direct human CFS data; dosing extrapolated from animal models
- Most practical for cognitive domain deficits (brain fog, processing speed) when IV protocols aren't feasible
- Selank
- Anxiolytic via BDNF modulation, IL-6 reduction
- Small human trials (anxiety disorders)
- 2–4 weeks (nasal or subcutaneous)
- Mechanism overlaps with SSRIs; limited CFS-specific research
- Consider as adjunct for CFS with prominent anxiety comorbidity
- Semax
- Cognitive enhancement, BDNF upregulation
- Small human trials (stroke recovery, cognitive enhancement)
- Similar to Selank. No CFS-specific trials
- Weaker evidence than Dihexa for synaptic effects; alternative if Dihexa unavailable